Cargando…

Accumulation of Temozolomide-Induced Apoptosis, Senescence and DNA Damage by Metronomic Dose Schedule: A Proof-of-Principle Study with Glioblastoma Cells

SIMPLE SUMMARY: Severe toxic side effects do not allow unlimited dose escalation of anticancer drugs, and the doses used in cancer therapy are therefore often rather low regarding the required target concentration. For temozolomide (TMZ), which is used in glioblastoma therapy, single high dose proto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beltzig, Lea, Stratenwerth, Björn, Kaina, Bernd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699541/ https://www.ncbi.nlm.nih.gov/pubmed/34944906 http://dx.doi.org/10.3390/cancers13246287

Ejemplares similares

Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics
por: Beltzig, Lea, et al.
Publicado: (2022)

Molecular Dosimetry of Temozolomide: Quantification of Critical Lesions, Correlation to Cell Death Responses, and Threshold Doses
por: Stratenwerth, Björn, et al.
Publicado: (2021)

Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells
por: Beltzig, Lea, et al.
Publicado: (2022)

Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells
por: Kaina, Bernd, et al.
Publicado: (2020)

Temozolomide – Just a Radiosensitizer?
por: Kaina, Bernd, et al.
Publicado: (2022)

Targeting c-IAP1, c-IAP2, and Bcl-2 Eliminates Senescent Glioblastoma Cells Following Temozolomide Treatment
por: Schwarzenbach, Christian, et al.
Publicado: (2021)

Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy. Comment on Strobel et al., Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. Biomedicines 2019, 7, 69
por: Kaina, Bernd
Publicado: (2019)

Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
por: He, Yang, et al.
Publicado: (2019)

On optimal temozolomide scheduling for slowly growing glioblastomas
por: Segura-Collar, Berta, et al.
Publicado: (2022)

Survival and Death Strategies in Glioma Cells: Autophagy, Senescence and Apoptosis Triggered by a Single Type of Temozolomide-Induced DNA Damage
por: Knizhnik, Anna V., et al.
Publicado: (2013)

Cytotoxic, Genotoxic and Senolytic Potential of Native and Micellar Curcumin
por: Beltzig, Lea, et al.
Publicado: (2021)

Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence
por: Berte, Nancy, et al.
Publicado: (2016)

A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

Antiangiogenesis in recurrent glioblastoma: proof of principle
por: Nossek, Erez, et al.
Publicado: (2009)

Erratum to: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

NETRIN-4 Protects Glioblastoma Cells FROM Temozolomide Induced Senescence
por: Li, Li, et al.
Publicado: (2013)

Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM
por: Tomicic, Maja T., et al.
Publicado: (2015)

Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
por: Wong, Eric T., et al.
Publicado: (2016)

Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
por: Tafuto, Salvatore, et al.
Publicado: (2019)

Comment in Response to “Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy etc. by B. Kaina”
por: Westhoff, Mike-Andrew, et al.
Publicado: (2020)

Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival
por: Robinson, C G, et al.
Publicado: (2010)

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
por: Koumarianou, Anna, et al.
Publicado: (2012)

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
por: De Divitiis, C., et al.
Publicado: (2016)

Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature
por: Tena, Isabel, et al.
Publicado: (2018)

Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors
por: Büsker, Sören, et al.
Publicado: (2022)

All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma
por: Cox, Maria Christina, et al.
Publicado: (2020)

Human Monocytes Undergo Excessive Apoptosis following Temozolomide Activating the ATM/ATR Pathway While Dendritic Cells and Macrophages Are Resistant
por: Bauer, Martina, et al.
Publicado: (2012)

Temozolomide induces senescence but not apoptosis in human melanoma cells
por: Mhaidat, N M, et al.
Publicado: (2007)

Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model
por: Ouyang, Mao, et al.
Publicado: (2016)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Extended-schedule dose-dense temozolomide in refractory gliomas
por: Berrocal, A., et al.
Publicado: (2009)

Mifepristone Overcomes Tumor Resistance to Temozolomide Associated with DNA Damage Repair and Apoptosis in an Orthotopic Model of Glioblastoma
por: Llaguno-Munive, Monserrat, et al.
Publicado: (2018)

Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells()
por: Cui, Bo, et al.
Publicado: (2010)

Metronomic Photodynamic Therapy with Conjugated Polymer Nanoparticles in Glioblastoma Tumor Microenvironment
por: Caverzán, Matías Daniel, et al.
Publicado: (2023)

Accelerated hyperfractionation plus temozolomide in glioblastoma
por: Kaul, David, et al.
Publicado: (2016)

Strategies of temozolomide in future glioblastoma treatment
por: Lee, Chooi Yeng
Publicado: (2017)

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
por: Saha, Dipongkor, et al.
Publicado: (2020)

Principles of Sequencing and Scheduling
por: Baker, Kenneth
Publicado: (2018)

Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids
por: Günther, W, et al.
Publicado: (2003)

Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation
por: Kast, Richard E.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_38j9kl9020e75jq1tu61084p61